Cognition Therapeutics Files Definitive Proxy Statement
Ticker: CGTX · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Cognition Therapeutics filed its proxy statement for the June 18 meeting - shareholders vote on company direction.
AI Summary
Cognition Therapeutics Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting on June 18, 2025. The filing outlines the company's governance and proposals to be voted on by shareholders. The company is based in Pittsburgh, PA, and operates in the biological products sector.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, executive compensation, and voting matters, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 20250428 — Filing Date (Date the definitive proxy statement was filed with the SEC.)
- 20250618 — Meeting Date (Date of the shareholder meeting for which the proxy statement is issued.)
Key Players & Entities
- COGNITION THERAPEUTICS INC (company) — Registrant
- 0001104659-25-040193.txt (document) — Filing document name
- 20250428 (date) — Filing date
- 20250618 (date) — Meeting date
- PITTSBURGH, PA (location) — Company headquarters
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit shareholder votes for their annual meeting, providing details on proposals, director nominees, and executive compensation.
When is the shareholder meeting for Cognition Therapeutics Inc.?
The shareholder meeting for Cognition Therapeutics Inc. is scheduled for June 18, 2025.
What is Cognition Therapeutics Inc.'s primary business sector?
Cognition Therapeutics Inc. is in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
Where is Cognition Therapeutics Inc. headquartered?
Cognition Therapeutics Inc. is headquartered at 2403 Sidney Street, Suite 261, Pittsburgh, PA 15203.
Was a fee required for this filing?
No fee was required for this filing, as indicated by the 'No fee required' checkbox being selected.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding COGNITION THERAPEUTICS INC (CGTX).